Skip to main
ZBH
ZBH logo

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 42%
Sell 6%
Strong Sell 3%

Bulls say

Zimmer Biomet Holdings is projecting sales of $7.85 billion for 2025, representing an increase of 4.0% year-over-year, alongside an anticipated adjusted EPS of $8.23, which reflects a growth of 2.9% compared to the previous year. The company reported that its SET sales grew by 8.4%, outpacing consensus expectations, highlighting robust performance in this segment, while knee and hip product lines are gaining traction due to successful new product launches and increased market penetration. Additionally, the recent ZimVie spin-off is expected to contribute to an expansion of operating margins over time, with management projecting an average annual margin expansion of +30 basis points, further enhancing the company’s financial outlook.

Bears say

The analysis of Zimmer Biomet Holdings reflects a negative outlook primarily due to anticipated sluggish revenue growth, projected at 2% or lower, exacerbated by underwhelming performance from the ROSA surgical robot and new product launches. Earnings expectations are further diluted by significant headwinds from foreign exchange fluctuations, with an estimated impact of 150-200 basis points, resulting in guidance for adjusted earnings per share that falls short of consensus estimates. Additionally, risks include underperformance in the orthopedic market, potential pricing pressures for implants, and integration challenges following recent acquisitions, all of which could hinder overall financial performance moving forward.

ZBH has been analyzed by 36 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 42% suggest Holding, 6% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Buy based on their latest research and market trends.

According to 36 analysts, ZBH has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.